Publications
Search our bibliography using the filters on the right-hand side.
Displaying 101 through 150 of 729 publications.
Skip to main content
Molnar D, La E, Verelst F, Curran D, Poston S, Van Bellinghen LA, Graham J. Assessing the public health impact of the adjuvanted respiratory syncytial virus prefusion F protein vaccine among older adults in the United States (US). Poster presented at the ISPOR 2023 Conference; May 8, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S172. doi: 10.1016/j.jval.2023.03.927
Poulos C, Gebben D, Peay H, Saha A, Vaezy S, Pierce A, Pina I, Farb A, Moultrie R, Babalola O, Tarver ME. Benefit-risk preferences of patients for the use of artificial intelligence and ultrasound imaging in different settings in echocardiography. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S349. doi: 10.1016/j.jval.2023.03.2378
Graham J, Kassouf W, Tomaras D, Kurt M, Patel M, Teitsson S. Cost-utility of nivolumab versus observation for the adjuvant treatment of urothelial carcinoma (UC) for patients who are at high-risk of recurrence: a Canada public payer perspective. Poster presented at the ISPOR 2023 Conference; May 8, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S66-7. doi: 10.1016/j.jval.2023.03.347
Verelst F, La E, Graham J, Molnar D. Leveraging time-use data to estimate market and non-market productivity losses due to respiratory syncytial virus (RSV) disease among adults aged ≥60 years in the United States (US). Poster presented at the ISPOR 2023 Conference; May 9, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S120. doi: 10.1016/j.jval.2023.03.632
Doane MJ, Boeri M, Vass C, Bussberg C, Panchmatia HR, Gasper S, Citrome L, Sajatovic M. Preferences for characteristics of oral antipsychotic treatments: survey results of patients living with schizophrenia or bipolar I disorder. Poster presented at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting; May 30, 2023. Miami Beach, FL.
Talbird SE, Anderson SA, Nossov M, Beattie N, Rak AT, Diaz-Mitoma F. Cost-effectiveness of a 3-antigen versus single-antigen vaccine for the prevention of hepatitis b in adults in the United States. Vaccine. 2023 May 26;41(23):3506-17. doi: 10.1016/j.vaccine.2023.04.022
Doane MJ, Boeri M, Vass CM, Bussberg CJ, Panchmatia HR, Gasper S, Citrome L, Sajatovic M. Preferences for characteristics of oral antipsychotic treatments: survey results of patients living with schizophrenia. Poster presented at the SIRS 2023 Congress; May 13, 2023. Toronto, Canada.
Davis A, Cook C, Graham J, Diaz-Decaro J, Myers E, Buck P. Modelling the public health impact of routine pediatric vaccination for the prevention of cytomegalovirus and congenital cytomegalovirus at the population-level. Poster presented at the 41st Annual Meeting of ESPID 2023; May 8, 2023. Lisbon, Portugal.
Perdrizet J, Horn EK, Hayford K, Grant L, Barry R, Huang L, McDade C, Wilson M. Historical population-level impact of infant 13-valent pneumococcal conjugate vaccine (PCV13) national immunization programs on invasive pneumococcal disease in Australia, Canada, England & Wales, Israel, and the United States. Infect Dis Ther. 2023 May;12(5):1351-64. doi: 10.1007/s40121-023-00798-x
George S, Carrico J, Hicks K, Loukov D, Ng C, Kaan I, Curran D. Cost-effectiveness and public health impact of recombinant zoster vaccine in immunocompromised adults in Canada. Poster presented at the 2023 Canadian Immunization Conference; April 25, 2023. Ottawa, Canada. Previously presented at the 2022 Canadian Association for Population Therapeutics Conference.
Morrison LTR, Anderson B, Brower A, Talbird SE, Buell N, MacDonald PDM, Metz L, Gaudig M, Oriol Mathieu V, Honeycutt AA. Macroeconomic impact of Ebola outbreaks in Sub-Saharan Africa and potential mitigation of GDP loss with prophylactic Ebola vaccination programs. PLoS One. 2023 Apr 11;18(4):e0283721. doi: 10.1371/journal.pone.0283721
Hauber B, Paulsen R, Krasa HB, Vradenburg G, Comer M, Callahan LF, Winfield J, Potashman M, Hartry A, Lee D, Wilson H, Hoffman DL, Weiberg D, Kremer IN, Taylor GA, Taylor JM, Lappin D, Martin AD, Frangiosa T, Biggar V, Slota C, Romano (DeMuro) C, DiBenedetti D. Assessing what matters to people affected by Alzheimer's disease: a quantitative analysis. Neurol Ther. 2023 Apr;12(2):505-27. doi: 10.1007/s40120-023-00445-0
Li X, Hodgson D, Flaig J, Kieffer A, Herring WL, Beyhaghi H, Willem L, Jit M, Bilcke J, Beutels P, REspiratory Syncytial virus Consortium in EUrope (RESCEU) Investigators. Cost-effectiveness of respiratory syncytial virus preventive interventions in children: a model comparison study. Value Health. 2023 Apr;26(4):508-18. doi: 10.1016/j.jval.2022.11.014
Bhattacharya R, Vass C, Pinto CA, Myers K, Imai K, Bussberg C, Calhoun SR, Poulos C. Exploring perceptions of the risk of recurrence in renal cell carcinoma: evidence from a survey of practicing physicians. Poster presented at the 2023 American Urological Association Annual Meeting; April 28, 2023. Chicago, IL. [abstract] J Urol. 2023 Apr 1; 209(Supplement 4):e271. doi: 10.1097/JU.0000000000003244.15
Mladsi D, Barnett CL, Mader G, Russell-Smith TA, Tuson H, Unuigbe A, Bell T. The zero-price conundrum: exploration of scenarios where a clinically effective new drug might not be cost-effective at zero price. Value Health. 2023 Mar;26(3):384-91. doi: 10.1016/j.jval.2023.01.004.
Huang L, McDade C, Perdrizet J, Wilson M, Warren S, Nzenze S, Sewdas R. Cost-effectiveness analysis of the South African infant national immunization program for the prevention of pneumococcal disease. Infect Dis Ther. 2023 Mar;12(3):933-50. doi: 10.1007/s40121-023-00767-4
Li D, Tan R, Hernandez S, Reilly N, Bussberg C, Mansfield C. Patient preferences for unresectable hepatocellular carcinoma treatments: a discrete-choice experiment. Cancers. 2023 Feb 25;15(5):1470. doi: 10.3390/cancers15051470
Molnar D, La E, Verelst F, Curran D, Poston S, Graham J. Modeling the clinical and economic burden of respiratory syncytial virus (RSV) among adults ≥60 years of age in the United States. Poster presented at the 2023 Respiratory Synctial Virus Foundation (RSVVW); February 22, 2023. Lisbon, Portugal.
Talbird S, Cook C, DeMartino J, Hernandez-Pastor L, Krishnarajah G. Projected impact of RSV vaccine in US adults ≥ 60 years of age. Poster presented at the 2023 Respiratory Synctial Virus Foundation (RSVVW); February 22, 2023. Lisbon, Portugal.
Vass C, Pinto CA, Myers K, Imai K, Bussberg C, Bhattacharya R, Calhoun SR, Poulos C. Heterogeneity in physician and patient preferences for the treatment of renal cell carcinoma: evidence from latent class analysis. Poster presented at the 2023 ASCO Genitourinary Cancers Symposium; February 16, 2023. San Franciso, CA. [abstract] J Clin Oncol. 2023 Feb 20; 41(Suppl 6):661. doi: 10.1200/JCO.2023.41.6_suppl.661
Calhoun SR, Vass C, Myers K, Imai K, Bussberg C, Bhattacharya R, Pinto CA, Poulos C. Patient and physician preferences for adjuvant treatment of renal cell carcinoma: a discrete-choice experiment. Poster presented at the 2023 ASCO Genitourinary Cancers Symposium; February 16, 2023. San Franciso, CA. [abstract] J Clin Oncol. 2023 Feb 20; 41(Suppl 6):635. doi: 10.1200/JCO.2023.41.6_suppl.635
Kandzari DE, Weber MA, Poulos C, Coulter J, Cohen SA, DeBruin V, Jones D, Pathak A. Patient preferences for pharmaceutical and device-based treatments for uncontrolled hypertension: discrete choice experiment. Circ Cardiovasc Qual Outcomes. 2023 Jan;16(1):e008997. doi: 10.1161/CIRCOUTCOMES.122.008997
Poulos C, Xu Y, Botha W, Leach C, Wrobleski KK, Gordon K, Missmer SA, Estes SJ. A discrete-choice experiment study of physicians' prioritization of attributes of medical treatments for endometriosis-associated pain. Expert Rev Pharmacoecon Outcomes Res. 2023 Jan;23(1):111-21. doi: 10.1080/14737167.2023.2152006
Bisanzio D, Davis AE, Talbird SE, Van Effelterre T, Metz L, Gaudig M, Mathieu VO, Brogan AJ. Targeted preventive vaccination campaigns to reduce Ebola outbreaks: an individual-based modeling study. Vaccine. 2022 Dec 14;S0264-410X(22):01449-9. doi: 10.1016/j.vaccine.2022.11.036
Ravelo A, Myers K, Brumble R, Bussberg C, Koffman B, Manzoor BS, Biondo J, Mansfield C. Understanding patient preferences for chronic lymphocytic leukemia treatments. Poster presented at the 64th ASH Annual Meeting and Exposition; December 12, 2022. New Orleans, LA.
Razavi M, Herring W, Gillis C, Maserejian N, Pemberton-Ross P, Nejati M. Economic burden of daily transitions to later stages of AD dementia in the US. Poster presented at the 15th Clinical Trials on Alzheimer's Disease (CTAD); December 2, 2022. San Francisco, CA.
Ni L, Diamantogiannis F, Teitsson S, Knight C. Cost-effectiveness analysis of nivolumab as an adjuvant treatment of muscle-invasive urothelial carcinoma at high risk of recurrence in Greece. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S120. doi: 10.1016/j.jval.2022.09.580
Paret K, Beyhaghi H, Herring W, Rousculp M, Toback S, Mauskopf J. Assessing the cost-effectiveness of the Novavax COVID-19 vaccine as a potential booster vaccine option for adults in the United States. Poster presented at the ISPOR Europe 2022; November 7, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S89. doi: 10.1016/j.jval.2022.09.434
Paret K, Ronquest N, Droege M. Economic modeling considerations for rare neurodegenerative diseases of infancy and early childhood. Poster presented at the ISPOR Europe 2022; November 9, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S171. doi: 10.1016/j.jval.2022.09.830
Mellott C, Jaworski R, Carrico J, Clinkscales M, Talbird S, Dobrowolska I, Golicki D, Tsoumani E, Sabale U. Public health impact and return on investment of the pediatric immunization program in Poland. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S117. doi: 10.1016/j.jval.2022.09.568
Lopez A, del Amo M, Perdizet J, McDade C, Wilson M. Comparing the public health impact of a 15- or 20-valent pneumococcal conjugate vaccine pediatric national immunization program in Spain. Poster presented at the ISPOR Europe 2022; November 7, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S99. doi: 10.1016/j.jval.2022.09.482
Talbird S, Graham J, Anderson S, Nossov M, Beattie N, Lains Sousa C, Rak A, Masters III H, Diaz-Mitoma F. Health and economic impact of a novel 3-antigen vaccine for the prevention of hepatitis B in adults in Germany: a cost-effectiveness analysis. Poster presented at the ISPOR Europe 2022; November 8, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S135. doi: 10.1016/j.jval.2022.09.649
Talbird S, Graham J, Anderson S, Nossov M, Beattie N, Lains Sousa C, Rak A, Masters III H, Diaz-Mitoma F. Cost-effectiveness and epidemiological impact of a novel 3-antigen vaccine for the prevention of Hepatitis B in adults in the United Kingdom. Poster presented at the ISPOR Europe 2022; November 8, 2022. Vienna, Austria. doi: 10.1016/j.jval.2022.09.782
Carrico J, Hicks K, Panozzo CA, Ghaswalla P. Economic burden of respiratory syncytial virus in adults in the United States. Poster presented at the ISPOR Europe 2022; November 7, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec; 25(12):S65. doi: 10.1016/j.jval.2022.09.315
Salem A, Curran D, Carrico J, La EM, Lorenc S, Hicks K, Poston S, Carpenter CF. Public health impact and cost-effectiveness of recombinant zoster vaccine for vaccinating immunocompromised adults against herpes zoster in the United States. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S159. doi: 10.1016/j.jval.2022.09.767
Li X, Hodgson D, Flaig J, Kieffer A, Herring W, Beyhaghi H, Willem L, Jit M, Bilcke J, Beutels P. Cost-effectiveness of Respiratory Syncytial Virus (RSV) prevention interventions in children: a model comparison study. Poster presented at the ISPOR Europe 2022; November 9, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec; 25(12S):S178. doi: 10.1016/j.jval.2022.09.861
Herring W, Shen Q, Zhang Y, Martin A, Otiker T, Zhang W. The relationship between Asthma Control Questionnaire scores and exacerbation risk, resource utilization, and utility values: an analysis from the CAPTAIN trial. Poster presented at the ISPOR Europe 2022; November 8, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S36. doi: 10.1016/j.jval.2022.09.174
Oniangue-Ndza C, Strittmatter G, Lucas A, Wilson M, Kassahun S, Singh P. Pharmacoeconomic analysis of adjuvant nivolumab for patients with resected esophageal or gastroesophageal junction cancer in Switzerland. Poster presented at the ISPOR Europe 2022; November 7, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S95. doi: 10.1016/j.jval.2022.09.464
Herring WL, Gould IG, Wittrup-Jensen V, Ertle J, Kuti E, Wolowacz S. Evaluation of emerging NASH therapies: the impact of treatment efficacy profiles on long-term health outcomes. J Comp Eff Res. 2022 Dec 1;11(18):1349-63. doi: 10.2217/cer-2021-0194
Bonastre J, Negrier S, Colrat F, Chamielec C, Teitsson S, Knight C, Ni L, Chevalier J, Gaudin AF, Roupret M, Branchoux S. Impact of method for modelling distant recurrence (DR) on cost-effectiveness (CE) of nivolumab (NIVO) as an adjuvant treatment of muscle-invasive urothelial carcinoma (MIUC) patients with high risk of recurrence in France. Presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria.
Poirrier JE, DeMartino JK, Nagar S, Carrico J, Hicks K, Meyers J, Stoddard J. Burden of opioid use for pain management among adult herpes zoster patients in the US and the potential impact of vaccination. Hum Vaccin Immunother. 2022 Nov;18(5):2040328. doi: 10.1080/21645515.2022.2040328
Petrillo J, Paret K, Sawant R, Koenig A, Wolowacz S, Ronquest N, Rickards H. Estimation of health state utilities in Huntington's disease: a targeted review. Poster presented at the HSG 2022 Annual Meeting; November 2022. Tampa, FL. [abstract] J Huntingtons Dis. 2022 Oct 31; 11(s1):S31. Previously presented at the European Huntington's Disease Network (EHDN) 2022 Plenary Meeting. doi: 10.3233/JHD-229005
Paret K, Beyhaghi H, Herring W, Rousculp M, Toback S, Mauskopf J. Population-level model of the health and economic impact of NVX-CoV2373 as a COVID-19 booster vaccine option for adults in the United States. Poster presented at the Society for Medical Decision Making (SMDM) 44th Annual North American Meeting; October 25, 2022. Seattle, WA.
Li D, Tan A, Hernandez S, Reilly N, Bussberg C, Mansfield C. Predicting treatment choices for unresectable hepatocellular carcinoma (HCC): results from a patient preference study. Poster presented at the AASLD 2022 The Liver Meeting; November 4, 2022. Washington, DC. [abstract] Hepatology. 2022 Oct 21; 76(S1):S1312. doi: 10.1002/hep.32697
Mader G, Mladsi D, Sanon M, Purser M, Barnett CL, Oberdhan D, Watnick T, Seliger S. A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease. BMC Nephrol. 2022 Oct 18;23(1):334. doi: 10.1186/s12882-022-02956-8
George S, Carrico J, Hicks K, Loukov D, Kaan I, Ng C, Regan J, Giannelos N. Updated cost-utility and public health impact of recombinant zoster vaccine (RZV) in Canadians aged 50 years and older. Poster presented at the 2022 Canadian Association for Population Therapeutics Conference; October 17, 2022. Toronto, Canada.
George S, Carrico J, Hicks K, Loukov D, Ng C, Kaan I, Curran D. Cost-effectiveness and public health impact of recombinant zoster vaccine in immunocompromised adults in Canada. Poster presented at the 2022 Canadian Association for Population Therapeutics Conference; October 17, 2022. Toronto, Canada.
Poulos C, Boeri M, Coulter JR, Huang L, Schley K, Pugh SJ. Travelers' preferences for tick-borne encephalitis vaccination. Expert Rev Vaccines. 2022 Oct 1;21(10):1495-504. doi: 10.1080/14760584.2022.2108798
Bell T, Fernandez M, Khan S, Tumminello B, Bektas M, Heyes CE, Oton AB. Patient burden of illness associated with desmoid tumors. Poster presented at the 2022 Desmond Tumor Research Foundation (DTRF) Annual Meeting; September 24, 2022. Philadelphia, PA.
Petrillo J, Paret K, Sawant R, Koenig A, Wolowacz S, Ronquest N, Rickards H. Estimation of health state utilities in Huntington's disease: a targeted review. Poster presented at the European Huntington's Disease Network (EHDN) 2022 Plenary Meeting; September 18, 2022. Bologna, Italy. [abstract] J Neurol Neurosurg Psychiatry. 2022 Sep 12; 93(suppl 1):A45-6. doi: 10.1136/jnnp-2022-ehdn.118